Parvovirus B19 transmission by a high‐purity factor VIII concentrate

200563 citationsJournal Article

Authors

Chuan-Ging Wu · Center for Biologics Evaluation and Research

Bobby L. Mason · Centers for Disease Control and Prevention

Julia Jong · Center for Biologics Evaluation and Research

Dean D. Erdman · The Centers

Laurel McKernan · Center for Biologics Evaluation and Research

Meredith Oakley · The Centers

Mike Soucie

Abstract

These findings and the recipient's clinical history support a causal relationship between the implicated AHF product and B19 infection in this recipient. The seronegative patient became infected after receiving 2x10(4) IU (or geq) of B19 DNA, which was present in this S/D-treated, high-purity AHF product.

Topics & Keywords

Parvovirus B19 Infection Studies Prenatal Screening and Diagnostics Dermatological and COVID-19 studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Transfusion

Volume 45, Issue 6, pp. 1003-1010

DOI: 10.1111/j.1537-2995.2005.04387.x

Field-Weighted Citation Impact: 4.41